IMMX
Immix Biopharma, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
13.60
▲ 0.44 (3.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.01
Prev close
13.16
Day high
13.76
Day low
13.12
Volume
1.51M
Market cap
$972.45M
P/E (TTM)
—
52W range
1.94 – 13.76
Day trading desk
Gap from prior close
-1.14%
Prior close 13.16
VWAP
13.50
+0.76% from price
Relative volume
0.77×
Normal
Session range
11.84%
12.50 – 13.98
Position in range
74%
Near session high
ATR (14D)
0.84
6.15% of price
Prior day high
13.20
PDH
Prior day low
12.69
PDL
Bid / ask spread
—
Quote not published
Session volume
1.41M
Avg 1.83M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+24.52%
+25.9%
1M
+55.23%
+51.5%
3M
+57.55%
+54.5%
6M
+70.75%
+59.7%
YTD
+161.19%
+148.9%
1Y
+523.74%
+503.7%
3Y
+671.75%
+597.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Flagged1
Total notional$67.50K
Call notional$67.50K
Put notional$0
Tiltcall-weighted
Likely opening1 of 1
| Side | Strike | Expiry | Volume | Open int. | Vol / OI | Notional | IV | Score | |
|---|---|---|---|---|---|---|---|---|---|
| CALL | 17.50 | Nov 20, 26 89d |
450 | 5 | 90.0× | $67.50K | 91% | at ask | 73 |
How this is calculated, and what it cannot see
A contract is flagged when today's volume approaches or exceeds its open interest, the position is worth at least $40,000, and at least 150 contracts changed hands. Open interest is what was outstanding at yesterday's close, so volume above it means the flow cannot all be closing — something is being opened.
The score weights four things: volume against open interest, dollar notional, volume against the rest of that chain, and where the last print sat inside the bid/ask spread.
What it cannot see. Volume here is a daily total, so ten small orders and one large one are indistinguishable — this is not block or sweep detection, which needs exchange-level time and sales. The print column compares the last trade to the current quote, which is a proxy for who was the aggressor, not a tagged flag. Quotes are delayed. A single large trade can be a hedge, a roll, or one leg of a spread, and none of those mean what a naked directional bet would mean.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IMMX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
12.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 22, 26 | ADAMS HELEN C Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | CHANG NANCY T Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | BUCHAN MELISSA JANE Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | MARQUET MAGDA Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | NG CAREY Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | HSU JASON Director |
STOCK | 6.25K | $0 | Direct |
| May 22, 26 | CHUDNOVSKY YEKATERINA Director |
STOCK | 6.25K | $0 | Direct |
| Dec 10, 25 | RACHMAN ILYA M Chief Executive Officer |
BUY | 746 | $4.98K | Direct |
| Dec 10, 25 | MORRIS GABRIEL S Chief Financial Officer |
BUY | 770 | $5.07K | Direct |
| Dec 8, 25 | MORRIS GABRIEL S Chief Financial Officer |
CONVERSION | 156.00K | $124.80K | Indirect |
| Sep 17, 25 | RACHMAN ILYA M Chief Executive Officer |
BUY | 2.50K | $5.05K | Direct |
| Sep 16, 25 | MORRIS GABRIEL S Chief Financial Officer |
BUY | 2.60K | $5.12K | Direct |
| Jun 18, 25 | RACHMAN ILYA M Chief Executive Officer |
BUY | 2.18K | $5.00K | Direct |
| Jun 18, 25 | MORRIS GABRIEL S Chief Financial Officer |
BUY | 2.23K | $5.07K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS HELEN C |
Director | 181.00K | Stock Award(Grant) |
BUCHAN MELISSA JANE |
Director | 28.70K | Stock Award(Grant) |
CHANG NANCY T |
Director | 925.13K | Stock Award(Grant) |
CHUDNOVSKY YEKATERINA |
Director | 3.25M | Stock Award(Grant) |
HSU JASON |
Director | 4.87M | Stock Award(Grant) |
MARQUET MAGDA |
Director | 72.34K | Stock Award(Grant) |
MORRIS GABRIEL S |
Chief Financial Officer | 742.41K | Purchase |
NG CAREY |
Director | 1.05M | Stock Award(Grant) |
RACHMAN ILYA M |
Chief Executive Officer | 1.14M | Purchase |
Fundamentals
Market cap$972.45M
Enterprise value$746.12M
Revenue (TTM)—
Gross profit—
EBITDA$-41.48M
Net income$-39.92M
EPS (TTM)$-0.88
Free cash flow$-25.39M
Total cash$232.11M
Total debt$1.00M
Book value / share$3.20
Shares outstanding71.19M
Float56.17M
Short % of float16.12%
Dividend yield—
Beta (5Y)0.11
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.11
PEG ratio—
Price / sales—
Price / book4.27
EV / revenue—
EV / EBITDA-17.99
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-34.18%
Return on assets-20.52%
Debt / equity0.44
Current ratio25.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $16.26M | $11.29M | $8.74M | $4.20M | +44.0% |
| Selling, general & admin | $13.70M | $11.38M | $7.41M | $4.02M | +20.3% |
| Total operating expense | $29.96M | $22.67M | $16.14M | $8.22M | +32.1% |
| Operating income | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -32.1% |
| Net interest income | $555.53K | $1.02M | $572.01K | -$497 | -45.4% |
| Pre-tax income | -$29.40M | -$21.66M | -$15.57M | -$8.22M | -35.8% |
| Tax provision | $37.72K | $41.04K | $26.41K | $10.27K | -8.1% |
| Net income | -$29.44M | -$21.61M | -$15.43M | -$8.23M | -36.2% |
| Net income to common | -$29.44M | -$21.61M | -$15.43M | -$8.23M | -36.2% |
| Basic EPS | -0.89 | -0.76 | -0.89 | -0.59 | -17.1% |
| Diluted EPS | -0.89 | -0.76 | -0.89 | -0.59 | -17.1% |
| EBIT | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -32.1% |
| EBITDA | -$29.59M | -$22.56M | -$16.14M | -$8.22M | -31.2% |
| Basic shares | 32.97M | 28.29M | 17.34M | 13.89M | +16.5% |
| Diluted shares | 32.97M | 28.29M | 17.34M | 13.89M | +16.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.93M | $17.68M | $17.51M | $13.44M | — | +431.2% |
| Cash & short-term investments | $100.41M | $17.68M | $17.51M | $13.44M | — | +467.9% |
| Total current assets | $101.24M | $20.20M | $19.79M | $14.90M | — | +401.2% |
| Property, plant & equipment | $3.49M | $2.73M | $50.18K | $3.56K | — | +27.8% |
| Total assets | $104.84M | $22.95M | $19.93M | $14.91M | — | +356.9% |
| Total current liabilities | $10.11M | $8.69M | $3.72M | $1.27M | — | +16.4% |
| Current debt | — | — | — | — | $50.00K | — |
| Total debt | $1.07M | $1.07M | $0 | — | $50.00K | -0.2% |
| Total liabilities | $11.04M | $9.70M | $3.72M | $1.75M | — | +13.9% |
| Retained earnings | -$104.46M | -$75.02M | -$53.41M | -$37.99M | — | -39.2% |
| Shareholder equity | $93.80M | $13.25M | $16.41M | $13.16M | — | +607.8% |
| Working capital | $91.13M | $11.51M | $16.07M | $13.62M | — | +691.7% |
| Net tangible assets | $93.80M | $13.25M | $16.41M | $13.16M | — | +607.8% |
| Shares issued | 53.02M | 27.61M | 19.99M | 13.96M | — | +92.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$29.44M | -$21.70M | -$15.60M | -$8.23M | — | -35.7% |
| Depreciation & amortisation | $364.50K | $115.39K | $5.47K | $2.13K | — | +215.9% |
| Stock-based compensation | $2.44M | $3.02M | $2.57M | $624.07K | — | -19.2% |
| Change in working capital | $2.70M | $3.97M | $1.65M | $195.21K | — | -31.9% |
| Operating cash flow | -$23.93M | -$14.60M | -$11.37M | -$7.41M | — | -64.0% |
| Capital expenditure | -$732.92K | -$1.18M | -$52.09K | — | -$802 | +37.8% |
| Investing cash flow | -$7.21M | -$1.18M | -$52.09K | $0 | — | -512.5% |
| Share buybacks | — | — | $0 | -$99.96K | $0 | — |
| Financing cash flow | $107.39M | $15.95M | $15.46M | $3.23M | — | +573.3% |
| Free cash flow | -$24.66M | -$15.77M | -$11.42M | -$7.41M | — | -56.4% |
| End cash position | $93.93M | $17.68M | $17.51M | $13.44M | — | +431.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $5.33M | $5.98M | $5.73M | $4.58M | $3.97M | — | -10.8% |
| Selling, general & admin | $7.12M | $4.82M | $5.17M | $3.08M | $2.75M | — | +47.7% |
| Total operating expense | $12.46M | $10.80M | $10.89M | $7.66M | $6.72M | — | +15.3% |
| Operating income | -$12.46M | -$10.80M | -$10.89M | -$7.66M | -$6.72M | — | -15.3% |
| Net interest income | $913.66K | $717.17K | $216.71K | $84.54K | $104.06K | — | +27.4% |
| Pre-tax income | -$11.54M | -$10.09M | -$10.68M | -$7.58M | -$6.61M | — | -14.4% |
| Tax provision | $14.32K | $0 | $11.27K | $7.72K | $8.91K | — | — |
| Net income | -$11.56M | -$10.09M | -$10.69M | -$7.59M | -$6.62M | — | -14.6% |
| Net income to common | -$11.56M | -$10.09M | -$10.69M | -$7.59M | -$6.62M | — | -14.6% |
| Basic EPS | -0.18 | -0.18 | — | -0.24 | -0.22 | -0.15 | 0.0% |
| Diluted EPS | -0.18 | -0.18 | — | -0.24 | -0.22 | -0.15 | 0.0% |
| EBIT | -$12.46M | -$10.80M | -$10.89M | -$7.66M | -$6.72M | — | -15.3% |
| EBITDA | -$12.33M | -$10.67M | -$10.80M | -$7.53M | -$6.64M | — | -15.5% |
| Basic shares | 63.77M | 55.37M | — | 31.93M | 29.98M | 29.70M | +15.2% |
| Diluted shares | 63.77M | 55.37M | — | 31.93M | 29.98M | 29.70M | +15.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.49M | $79.25M | $93.93M | $15.95M | $11.64M | +184.5% |
| Cash & short-term investments | $232.11M | $90.58M | $100.41M | $15.95M | $11.64M | +156.2% |
| Total current assets | $233.79M | $92.27M | $101.24M | $16.58M | $12.33M | +153.4% |
| Property, plant & equipment | $3.25M | $3.36M | $3.49M | $3.36M | $3.18M | -3.3% |
| Total assets | $239.11M | $95.82M | $104.84M | $20.08M | $15.64M | +149.5% |
| Total current liabilities | $9.30M | $10.54M | $10.11M | $10.85M | $10.01M | -11.7% |
| Total debt | $1.00M | $1.04M | $1.07M | $1.11M | $1.04M | -3.5% |
| Total liabilities | $10.19M | $11.45M | $11.04M | $11.82M | $10.98M | -11.0% |
| Retained earnings | -$126.11M | -$114.55M | -$104.46M | -$93.78M | -$86.19M | -10.1% |
| Shareholder equity | $228.92M | $84.36M | $93.80M | $8.26M | $4.65M | +171.3% |
| Working capital | $224.49M | $81.74M | $91.13M | $5.73M | $2.32M | +174.7% |
| Net tangible assets | $228.92M | $84.36M | $93.80M | $8.26M | $4.65M | +171.3% |
| Shares issued | 71.19M | 53.08M | 53.02M | 33.11M | 28.48M | +34.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$11.56M | -$10.09M | -$10.69M | -$7.59M | -$6.62M | -14.6% |
| Depreciation & amortisation | $130.88K | $130.77K | $90.63K | $134.85K | $79.83K | +0.1% |
| Stock-based compensation | $978.14K | $575.57K | $570.80K | $470.47K | $532.25K | +69.9% |
| Change in working capital | -$1.25M | -$470.34K | -$1.00M | $1.07M | $700.70K | -165.5% |
| Operating cash flow | -$11.74M | -$9.83M | -$11.03M | -$5.91M | -$5.31M | -19.4% |
| Capital expenditure | -$21.04K | -$32.49K | -$165.13K | -$372.46K | -$127.63K | +35.2% |
| Investing cash flow | $2.67M | -$4.80M | -$6.65M | -$372.46K | -$127.63K | +155.6% |
| Financing cash flow | $155.28M | -$37.56K | $95.67M | $10.61M | $1.11M | +413,515.5% |
| Free cash flow | -$11.76M | -$9.86M | -$11.19M | -$6.28M | -$5.44M | -19.2% |
| End cash position | $225.49M | $79.25M | $93.93M | $15.95M | $11.64M | +184.5% |
Options analytics
Put / call volume
3.69
Put-heavy session
Put / call open interest
0.06
Positioning, not flow
Max pain
10.00
-26.8% from spot
ATM implied vol
100.4%
Nearest strike to spot
Skew (10% OTM)
+6.4%
Puts bid over calls
Call volume
29
Contracts, this expiry
Put volume
107
Contracts, this expiry
Heaviest call OI
12.50
376 contracts
Heaviest put OI
7.50
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.18 | -0.18 | -2.4% |
| Mar 2026 | -0.21 | -0.18 | +13.3% |
| Dec 2025 | -0.16 | -0.28 | -75.0% |
| Sep 2025 | -0.19 | -0.24 | -26.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.19 | 6 | $0 | 0.0% |
| Next quarter | -0.20 | 6 | $0 | 0.0% |
| Current year | -0.74 | 8 | $0 | 0.0% |
| Next year | -0.90 | 8 | $12.99M | 0.0% |
Analyst targets & ownership
Mean target$20.28
High target$27.00
Low target$13.20
Implied upside49.08%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy3 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders17.13%
Held by institutions78.88%
Institutions holding141
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.80
+15.22% from price
SMA 20
10.36
+31.80% from price
SMA 50
10.03
+36.13% from price
SMA 100
9.65
+41.00% from price
SMA 200
7.98
+71.12% from price
EMA 12
11.71
+16.15% from price
EMA 26
10.79
+26.02% from price
EMA 50
10.22
+33.11% from price
RSI (14)
74.5
Overbought
MACD (12,26,9)
0.92
Hist 0.40
ATR (14)
0.84
6.12% of price
Realised vol 30D
90.0%
Annualised
Bollinger upper
13.76
20, 2σ
Bollinger lower
6.97
20, 2σ
50 / 200 cross
Golden
10.03 vs 7.98
Trend bias
Above 200
+71.12%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.56
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
90.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.8%
Peak to trough
Max drawdown 5Y
-88.9%
Peak to trough
ATR 14
0.84
6.12% of price
Beta (reported)
0.11
5Y monthly, from filing
Short interest
Shares short
9.49M
Prior 7.88M
Change vs prior
+20.4%
Shorts adding
% of float
16.12%
Elevated
% of shares out
13.33%
Against total outstanding
Days to cover
5.1
Crowded exit
Float
56.17M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 22, 26 | Needham | INITIATED | — | Buy |
| Jun 18, 26 | B of A Securities | INITIATED | — | Buy |
| Jun 17, 26 | LifeSci Capital | INITIATED | — | Outperform |
| May 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 30, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 27, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 25, 26 | Morgan Stanley | INITIATED | — | Overweight |
| Mar 9, 26 | Citizens | INITIATED | — | Market Outperform |
SEC filings
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-06
Corporate Changes & Voting Matters
8-K · 2026-03-30
Periodic Financial Reports
10-K/A · 2026-03-27
Headlines
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
MT Newswires · 12d ago
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · 19d ago
Needham Initiates Immix Biopharma at Buy With $21 Price Target
MT Newswires · 32d ago
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
Investor's Business Daily · 32d ago
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
Zacks · 66d ago
BofA Initiates Immix Biopharma at Buy With $27 Price Target
MT Newswires · 66d ago
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St. · 75d ago
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
Zacks · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.